A Billion Dollar Solution for Inflammatory Bowel Disease
Sanofi (Nasdaq: SNY) and Teva Pharmaceuticals (NYSE: TEVA) will collaborate to deliver a treatment for inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and affects more than 10 million people worldwide.
The collaboration will leverage the innovative R&D and commercial expertise of both companies as they evaluate TEV ‘574 as a treatment for IBD. Initial program results are expected to be available in 2024.
Under the terms of the new collaboration agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones.
Highlights
TEV ‘574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease.
Each company will equally share the development costs globally and Sanofi will lead the development of the Phase 3 program.
The collaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases.
Inflammatory bowel disease includes two conditions — Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal tract. An estimated ~10 million people worldwide live with IBD.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
